Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: Results of a consensus process by gruppo italiano trapianto di midollo osseo (GITMO)

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1226-1236

  Girmenia, Corrado ^a   Barosi, Giovanni ^c,n   Averse, Franco ^e   Bacigalupo, Andrea ^f   Barbui, Tiziano ^h   Beronciani, Donatella ^c   Bosi, Alberto ^j   Candoni, Anna ^k   Locasciulli, Anna ^b,i   Locatelli, Franco ^d   Menichetti, Francesco ^l   Musso, Maurizio ^m   Viscoli, Claudio ^g   Rambaldi, Alessandro ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c Unit of Clinical Epidemiology   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Ospedele S Martino ^*

^g UNIVERSITY OF GENOA   (Italy)

^h OSPEDALI RIUNITI   (Italy)

ⁱ Ospedale Oncologico A Businco   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k UNIVERSITY OF UDINE   (Italy)

^l CISANELLO HOSPITAL   (Italy)

^m LA MADDALENA CANCER CENTER   (Italy)

ⁿ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DIAZEPAM; DIGOXIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; LOPERAMIDE; METHYLPREDNISOLONE; MICAFUNGIN; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TEMAZEPAM; TRIAZOLAM; UNINDEXED DRUG; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; CANDIDIASIS; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; INFECTION RISK; MEDICAL RESEARCH; MEDICAL SOCIETY; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; ITALY; MYCOSES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 70349932352     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605665     Document Type: Review

References (65)

1. 1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917 (Pubitemid 34229758)
2. 2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366 (Pubitemid 35429674)
3. 3. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-833 (Pubitemid 36917771)
4. 4. Saavedra S, Sanz GF, Jarque I, et al Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 2002;30:937-943 (Pubitemid 36097484)
5. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late post transplant infections in adult and pediatric patients 1996-2005. Medicine Baltimore 2007; 86: 324-333
6. 6. Miyakoshi S, Kusumi E, Matsumura T, et al Invasive fungal infection following reducedintensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007; 13:771-777 (Pubitemid 46902432)
7. 7. Parody R, Martino R, Rovira M, et al Severe infections after unrelated donor allogeneic hematopoietic stem celltransplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12:734-748 (Pubitemid 43899409)
8. Barker JN, Hough RE, van Burik JA, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant 2005; 11:362-370
9. 9. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007; 13:1249-1267 (Pubitemid 47571038)
10. 10. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-610 (Pubitemid 46233255)
11. Garcia-Vidal C, Upton A, Kirby KA, Marr A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47:1041-1050
12. 12. Pagano L, Caira M, Nosari A, et al Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-1170 (Pubitemid 47580314)
13. William PL, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs 1994; 19:180-186
14. Delbecq AL, van de Ven AH, Gustafson DH. Group techniques for program planning: a guide to nominal group and Delphi processes. Glenview, IL: Scott, Foresman and Company, 1975.
15. Dykewicz CA; Centers for Disease Control and Prevention (U.S.);Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144
16. 16. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360 (Pubitemid 351265310)
17. Pappas PG, Kauffman CA, Andes D, et al Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535
18. 18. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stemcell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-5489 (Pubitemid 350232225)
19. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552
20. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851
21. 21. Marr K, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061 (Pubitemid 30696231)
22. 22. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000;25:853-859 (Pubitemid 30209678)
23. 23. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002;71:260-267 (Pubitemid 35396942)
24. 24. Rijnders BJ, Cornelissen JJ, Slobbe L, et al Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408 (Pubitemid 351589940)
25. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for longterm antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138:705-713
26. 26. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungai infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533 (Pubitemid 38168674)
27. 27. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416 (Pubitemid 39518200)
28. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.N Engl J Med 2007;356:335-347
29. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients [abstract 163]. Blood (ASH Annual Meeting Abstracts) 2007; 110.
30. 30. Maertens JA, Frere P, Lass-Florl C, Heinz W, Comely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007; 43(Suppl 5):43-48. (Pubitemid 47193191)
31. Comely OA, Böhme A, Reichert D, et al Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008;61:939-946
32. 32. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008;61:734-742 (Pubitemid 351321154)
33. 33. Grigg A, Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 2008; 10:3-12. (Pubitemid 351171318)
34. de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007;40:245-9.
35. Nosari A, Ravini M, Cairoli R, et al. Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39:631-635
36. 36. Martino R, Parody R, Fukuda T, et al Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108:2928-2936 (Pubitemid 44776928)
37. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006;42:1584-1591
38. 38. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-409 (Pubitemid 46147624)
39. 39. Maertens J, Theunissen K, Verhoef G, et al Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-1250 (Pubitemid 41534660)
40. 40. Maertens J, Deeren D, Dierickx D, Theunissen K. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006; 19:551-556 (Pubitemid 44665460)
41. 41. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005; 159:181-188 (Pubitemid 40633920)
42. Asano-Mori Y, Kanda Y, Oshima K, et al Falsepositive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61 : 411-416
43. 43. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297-1306 (Pubitemid 35193008)
44. De Pauw B, Walsh TJ, Donnelly JP, et al Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
45. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-9.
46. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-649
47. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-1427
48. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med 2002; 346: 222-231
49. 49. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-990 (Pubitemid 37168186)
50. Cherif H, Kalin M, Björkholm M. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? Eur J Haematol 2006; 77:288-292
51. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771
52. 52. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135:412-422 (Pubitemid 32845866)
53. 53. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234 (Pubitemid 34438861)
54. 54. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-1402 (Pubitemid 39288165)
55. 55. Cisneros JM, Espigado I, Rivero A, et al. Empirical antifungal therapy in selected patients with persistent fever and neutropenia. Enferm. Infecc Microbiol Clin 2005;23:609-614 (Pubitemid 43010295)
56. Rodríguez MM, Serena C, Mariné M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008;52:3786-3788
57. 57. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-371 (Pubitemid 352009357)
58. 58. Perkhofer S, Locher M, Cuenca-Estrella M, et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother 2008; 52:2636-2638 (Pubitemid 351915698)
59. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24-34.
60. 60. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106:4397-4406 (Pubitemid 41775954)
61. Bellocchio S, Bozza S, Montagnoli C, et al Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Med Mycol 2005;43(Suppl 1):S181-8.
62. 62. Perruccio K, Bozza S, Montagnoli C, et al Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol Dk 2004;33:248-255 (Pubitemid 39446494)
63. 63. Granell M, Urbano-Ispizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006;34:1435-1441 (Pubitemid 44374841)
64. 64. Vekemans M, Robinson J, Georgala A, et al. Low mannose-binding lectin concentration is associated with, severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis 2007; 44: 1593-1601 (Pubitemid 46871506)
65. Bochud PY, Chien JW, Marr KA, et al. Tolllike receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-1777